The risk of colitis recurrence was increased if patients had a longer duration of symptoms and required immune-suppression for initial colitis, whereas resumption of anti–PD-1/L1 led to lower risk than resumption of anti–CTLA-4. Here, CTLA4 is linked to colitis.